

IZBORNOM VE U MEDICINSKOG FAKULTETA UNIVERZITETA U BEOGRADU

Komisija za pripremu referata u sastavu:

1. Prof. dr Dušan Popadi , redovni profesor Medicinskog fakulteta Univerziteta u Beogradu
2. Prof. dr Vera Pravica, redovni profesor Medicinskog fakulteta Univerziteta u Beogradu
3. Prof. dr Marija Mostarica Stojkovi , profesor emeritus Medicinskog fakulteta Univerziteta u Beogradu

odre ena na sednici Izbornog ve a Medicinskog fakulteta u Beogradu održanoj 05.07.2017. godine, analizirala je prijave na konkurs raspisan u oglasnim novinama „Poslovi“, objavljenom 05.07.2017. godine za izbor jednog nastavnika u zvanje redovnog profesora za užu nau nu oblast Imunologija, i podnosi slede i

R E F E R A T

Na raspisani konkurs se prijavio jedan kandidat: Prof. dr Vladimir Trajkovi

A. OSNOVNI BIOGRAFSKI PODACI

- Ime, srednje ime i prezime: Vladimir S. Trajkovi
- Datum i mesto ro enja: 27.04.1967.
- Ustanova gde je zaposlen: Medicinski fakultet Univerziteta u Beogradu
- Zvanje/radno mesto: Vanredni profesor
- Nau na oblast: Imunologija

B. STRU NA BIOGRAFIJA, DIPLOME I ZVANJA

Osnovne studije

- Naziv ustanove: Medicinski fakultet Univerziteta u Beogradu
- Mesto i godina završetka, prose na ocena: Beograd, 1994., 9,00

Poslediplomske studije

- Naziv ustanove: Medicinski fakultet Univerziteta u Beogradu
- Mesto, godina završetka i članovi komisije: Beograd, 1998., prof. dr Vojislav Panti , doc. dr Milutin Miri i prof. dr Marija Mostarica Stojkovi (mentor)
- Naslov magistarskog rada: Korelacija izme u produkcije azotnog oksida i imunološke reaktivnosti kod pacova
- Uža nau na oblast: Imunologija

Doktorat

- Naziv ustanove: Medicinski fakultet Univerziteta u Beogradu
- Mesto i godina odbrane i članovi komisije: Beograd, 2001., prof. dr Bogdan uri i , prof. dr Zorica Rami i prof. dr Marija Mostarica Stojkovi (mentor)
- Naslov disertacije: Uloga interleukina-18 u regulaciji imunskog odgovora
- Uža nau na oblast: Imunologija

Specijalizacija

Specijalisti ki ispit iz Imunologije položio je sa odli nom ocenom 2011. godine na Medicinskom fakultetu Univerziteta u Beogradu.

Dosadašnji izbori u nastavna i nau na zvanja

- 06.12.2011. vanredni profesor
- 17.02.2006. docent
- 14.06.2001. asistent
- 04.06.1998. asistent pripravnik

OBAVEZNI USLOVI

C. OCENA O REZULTATIMA PEDAGOŠKOG RADA

Prof. dr Vladimir Trajkovi u estvuje u održavanju teorijske, seminarske i prakti ne nastave iz predmeta Imunologija (u proseku 90 asova po školskoj godini) za studente druge godine integrisanih akademskih studija medicine na Medicinskom fakultetu Univerziteta u Beogradu. Godišnje ispita usmeno u proseku 150 studenata na ovom predmetu. Tako e u estvuje u organizovanju i izvo enju nastave iz izbornog predmeta Imunoregulacija (u proseku 35 asova po školskoj godini). U okviru poslediplomske nastave u estvuje na Specijalisti kim akademskim studijama i specijalisti kim studijama iz oblasti Imunologije, Reumatologije, Dermatovenerologije i Mikrobiologije sa parazitologijom (u proseku 25 asova po školskoj godini), a u estvuje i u izvo enju nastave iz

predmeta Osnovi mikrobiologije i imunologije na Specijalisti kim strukovnim studijama na Medicinskom fakultetu Univerziteta u Beogradu (6 asova). Kvalitet nastave prof. dr Vladimira Trajkovića ocenjen je ocenom 4,41 (od 5) od strane studenata integrisanih akademskih studija medicine Medicinskog fakulteta Univerziteta u Beogradu.

D. OCENA REZULTATA U OBEZBEĐIVANJU NAUČNO-NASTAVNOG PODMLATKA

Prof. dr Vladimir Trajković je bio mentor 5 odbranih doktorskih disertacija (4 na Medicinskom fakultetu i 1 na Biološkom fakultetu Univerziteta u Beogradu), kao i komentor 1 odbranjene doktorske disertacije na Medicinskom fakultetu Univerziteta u Beogradu. Takođe je mentor je 4 prijavljene doktorske disertacije na Medicinskom fakultetu Univerziteta u Beogradu, a 5 puta je bio član komisije za odbranu doktorskih disertacija na Medicinskom fakultetu Univerziteta u Beogradu. Mentor je jednog završnog rada na specijalisti kim akademskim studijama na Medicinskom fakultetu Univerziteta u Beogradu.

Doktorske disertacije:

- „Uticaj van elijske acidoze na produkciju azot monoksida, vijabilitet tumorskih ćelija i citotoksi na svojstva makrofaga miša i pacova in vitro“, Ljubica Harhaji, odbranjena 2006. god. na Biološkom fakultetu Univerziteta u Beogradu, mentor
- „Uticaj metformina na apoptozu ćelija glioma i melanoma in vitro i na rast melanoma in vivo“, Kristina Janjetović, odbranjena 2014. god. na Medicinskom fakultetu Univerziteta u Beogradu, mentor
- „Uticaj interleukina-17 na mezenhimske matične ćelije kostne srži miša u in vitro uslovima“, Slavko Mojsilović, odbranjena 2014. na Medicinskom fakultetu Univerziteta u Beogradu, mentor
- „Modulacija diferencijacije i funkcije humanih Langerhansovih ćelija monocitnog porekla in vitro“, Ivan Rajković, odbranjena 2015. na Medicinskom fakultetu Univerziteta u Beogradu, mentor
- „Mehanizmi citotoksičnog i citoprotektivnog dejstva fulerenskih (C₆₀) nanoestrica“, Maja Misirkić, odbranjena 2015. god. na Medicinskom fakultetu Univerziteta u Beogradu, mentor
- „Proinflamatorni i antit inflamatorni citokini kao pokazatelji operativne traume i stepena tkivnog oštećenja kod laparoskopske i konvencionalne holecistektomije“, Srđan Mijatović, odbranjena 2017. god. na Medicinskom fakultetu Univerziteta u Beogradu, komentor

E. NAUČNI ISTRUČNI RAD

a) Hronološkim redom navesti spisak objavljenih radova prema priloženoj tabeli klasifikacije radova

Originalni radovi in extenso u časopisima sa JCR liste:

1. Pantović A, Bosnjak M, Arsić K, Kosic M, Mandić M, Ristić B, Tosić J, Grujić D, Isaković A, Micić N, Trajković V, Harhaji-Trajković L. In vitro antiglioma action of indomethacin is mediated via AMP-activated protein kinase/mTOR complex 1 signalling pathway. *Int J Biochem Cell Biol* 2017;83:84-96. (IF = 3.505, M22)
2. Sumarac-Dumanović M, Apostolović M, Janjetović K, Jeremić D, Popadić D, Ljubić A, Micić J, Dukanac-Stamenković J, Tubić A, Stevanović D, Micić D, Trajković V. Downregulation of autophagy gene expression in endometria from women with polycystic ovary syndrome. *Mol Cell Endocrinol* 2017;440:116-124. (IF = 3.754, M22)
3. Isaković AM, Dulović M, Marković I, Kravić-Stević T, Bumbasirević V, Trajković V, Isaković A. Autophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition-induced apoptotic death. *Exp Cell Res* 2017;350:32-40. (IF = 3.546, M22)
4. Paunović V, Kosic M, Djordjević S, Žugic A, Djalinać N, Gasić U, Trajković V, Harhaji-Trajković L. Marrubium vulgare ethanolic extract induces proliferation block, apoptosis, and cytoprotective autophagy in cancer cells in vitro. *Cell Mol Biol (Noisy-le-grand)* 2016;62:108-114. (IF = 0.920, M23)
5. Kosic M, Arsić-Csordas K, Paunović V, Firestone RA, Ristić B, Mircić A, Petricević S, Bosnjak M, Zogović N, Mandić M, Bumbasirević V, Trajković V, Harhaji-Trajković L. Synergistic anticancer action of lysosomal membrane permeabilization and glycolysis inhibition. *J Biol Chem* 2016;291:22936-22948. (IF = 4.125, M21)
6. Stanković MS, Janjetović K, Velimirović M, Milenković M, Stojković T, Puskas N, Zaletel I, De Luka SR, Janković S, Stefanović S, Japundžić-Zigon N, Petronijević ND, Trajković V, Trbović AM. Effects of IL-33/ST2 pathway in acute inflammation on tissue damage, antioxidative parameters, magnesium concentration and cytokines profile. *Exp Mol Pathol* 2016;101:31-37. (IF = 2.423, M22)
7. Simović Marković B, Nikolić A, Gazdović M, Bojić S, Vucicević L, Kosic M, Mitrović S, Milosavljević M, Besra G, Trajković V, Arsenijević N, Lukić ML, Volarević V. Galectin-3 plays an important pro-inflammatory role in the induction phase of acute colitis by promoting activation of NLRP3 inflammasome and production of IL-1 in macrophages. *J Crohn's Colitis* 2016;10:593-606. (IF = 5.813, M21)
8. Hulea L, Marković Z, Topisirović I, Simmet T, Trajković V. Biomedical potential of mTOR modulation by nanoparticles. *Trends Biotechnol* 2016;34:349-53. (IF = 11.126, M21)

9. Klionsky DJ, Abdelmohsen K, Abe A... Trajkovic V... et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 2016;12:1-222. (IF = 8.593, M21)
10. Jevti G, Nikoli T, Mir i A, Stojkovi T, Velimirovi M, Trajkovi V, Markovi I, Trbovich AM, Radonji NV, Petronijevi ND. Mitochondrial impairment, apoptosis and autophagy in a rat brain as immediate and long-term effects of perinatal phencyclidine treatment - influence of restraint stress. *Prog Neuropsychopharmacol Biol Psychiatry* 2016;66:87-96. (IF = 4.187, M21)
11. Paunovic V, Ristic B, Markovic Z, Todorovic-Markovic B, Kosic M, Prekodravac J, Kravic-Stevovic T, Martinovic T, Micusik M, Spitalsky Z, Trajkovic V, Harhaji-Trajkovic L. c-Jun N-terminal kinase-dependent apoptotic photocytotoxicity of solvent exchange-prepared curcumin nanoparticles. *Biomed Microdevices* 2016;18:37. (IF = 2.062, M22)
12. Vilimanovich U, Bosnjak M, Bogdanovic A, Markovic I, Isakovic A, Kravic-Stevovic T, Mircic A, Trajkovic V, Bumbasirevic V. Statin-mediated inhibition of cholesterol synthesis induces cytoprotective autophagy in human leukemic cells. *Eur J Pharmacol* 2015;765:415-28. (IF = 2.730, M22)
13. Popovic M, Stanojevic Z, Tosic J, Isakovic A, Paunovic V, Petricevic S, Martinovic T, Ciric D, Kravic-Stevovic T, Soskic V, Kostic-Rajacic S, Shakib K, Bumbasirevic V, Trajkovic V. Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats. *J Neurochem* 2015;135:125-38. (IF = 3.842, M21)
14. Popadic S, Savic E, Markovic M, Ramic Z, Medenica L, Pravica V, Spuran Z, Trajkovic V, Popadic D. TNF, IL12B, and IFNG gene polymorphisms in Serbian patients with psoriasis. *Ann Dermatol* 2015;27:128-32. (IF = 1.325, M23)
15. Zogovic N, Tovilovic-Kovacevic G, Misirkic-Marjanovic M, Vucicevic L, Janjetovic K, Harhaji-Trajkovic L, Trajkovic V. Coordinated activation of AMP-activated protein kinase, extracellular signal-regulated kinase, and autophagy regulates phorbol myristate acetate-induced differentiation of SH-SY5Y neuroblastoma cells. *J Neurochem* 2015;133:223-32. (IF = 3.842, M21)
16. Volarevic V, Misirkic M, Vucicevic L, Paunovic V, Simovic Markovic B, Stojanovic M, Milovanovic M, Jakovljevic V, Micic D, Arsenijevic N, Trajkovic V, Lukic ML. Metformin aggravates immune-mediated liver injury in mice. *Arch Toxicol* 2015;89:437-50. (IF = 6.637, M21)
17. Volarevic V, Markovic BS, Bojic S, Stojanovic M, Nilsson U, Leffler H, Besra GS, Arsenijevic N, Paunovic V, Trajkovic V, Lukic ML. Gal-3 regulates the capacity of dendritic cells to promote NKT-cell-induced liver injury. *Eur J Immunol* 2015;45:531-43. (IF = 4.179, M21)
18. Vucicevic L, Misirkic-Marjanovic M, Paunovic V, Kravic-Stevovic T, Martinovic T, Ciric D, Maric N, Petricevic S, Harhaji-Trajkovic L, Bumbasirevic V, Trajkovic V. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. *Autophagy* 2014;10:2362-78. (IF = 11.753, 21)
19. Volarevic V, Paunovic V, Markovic Z, Simovic Markovic B, Misirkic-Marjanovic M, Todorovic-Markovic B, Bojic S, Vucicevic L, Jovanovic S, Arsenijevic N, Holclajtner-Antunovic I, Milosavljevic M, Dramicanin M, Kravic-Stevovic T, Ciric D, Lukic ML, Trajkovic V. Large graphene quantum dots alleviate immune-mediated liver damage. *ACS Nano* 2014;8:12098-109. (IF = 12.881, 21)
20. Ristic B, Bosnjak M, Arsikin K, Mircic A, Suzin-Zivkovic V, Bogdanovic A, Perovic V, Martinovic T, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L. Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells. *Exp Cell Res* 2014;326:90-102. (IF = 3.246, 22)
21. Tovilovic G, Ristic B, Milenkovic M, Stanojevic M, Trajkovic V. The role and therapeutic potential of autophagy modulation in controlling virus-induced cell death. *Med Res Rev* 2014;34:744-67. (IF = 8.431, 21)
22. Jokanovi V, olovi B, Jokanovi B, Rudolf R, Trajkovi V. Relationship between activity of silica thin films and density of cells occupation. *J Biomed Mater Res A* 2014;102:1707-14. (IF = 3.369, 21)
23. Stevanovic DM, Grefhorst A, Themmen AP, Popovic V, Holstege J, Haasdijk E, Trajkovic V, van der Lely AJ, Delhanty PJ. Unacylated ghrelin suppresses ghrelin-induced neuronal activity in the hypothalamus and brainstem of male rats. *PLoS One* 2014;9:e98180. (IF = 3.234, 21)
24. Ristic BZ, Milenkovic MM, Dakic IR, Todorovic-Markovic BM, Milosavljevic MS, Budimir MD, Paunovic VG, Dramicanin MD, Markovic ZM, Trajkovic VS. Photodynamic antibacterial effect of graphene quantum dots. *Biomaterials* 2014;35:4428-35. (IF = 8.557, 21)
25. Bosnjak M, Ristic B, Arsikin K, Mircic A, Suzin-Zivkovic V, Perovic V, Bogdanovic A, Paunovic V, Markovic I, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L. Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death. *PLoS One* 2014;9:e94374. (IF = 3.234, 21)
26. Ili DR, Jevti VV, Radi GP, Arsikin K, Risti B, Harhaji-Trajkovi L, Vukovi N, Sukdolac S, Klisuri O, Trajkovi V, Trifunovi SR. Synthesis, characterization and cytotoxicity of a new palladium(II) complex with a coumarine-derived ligand. *Eur J Med Chem* 2014;74:502-8. (IF = 3.447, 21)

27. Trifunovi S, Isakovi AM, Isakovi A, Vu kovi I, Mandi B, Novakovi M, Vajs V, Milosavljevi S, Trajkovi V. Isolation, characterization, and in vitro cytotoxicity of new sesquiterpenoids from *Achillea clavennae*. *Planta Med* 2014;80:297-305. (IF = 2.152, 21)
28. Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, Paunovic V, Ardah MT, El-Agnaf OM, Kostic V, Markovic I, Trajkovic V. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. *Neurobiol Dis* 2014;63:1-11. (IF = 5.087, 21)
29. Stevanovic D, Trajkovic V, Müller-Lüthloff S, Brandt E, Abplanalp W, Bumke-Vogt C, Liehl B, Wiedmer P, Janjetovic K, Starcevic V, Pfeiffer AF, Al-Hasani H, Tschöp MH, Castañeda TR. Ghrelin-induced food intake and adiposity depend on central mTORC1/S6K1 signaling. *Mol Cell Endocrinol* 2013;381(1-2):280-90. (IF = 4.241, 21)
30. Jeremic I, Tadic V, Isakovic A, Trajkovic V, Markovic I, Redzic Z, Isakovic A. The mechanisms of in vitro cytotoxicity of mountain tea, *Sideritis scardica*, against the C6 glioma cell line. *Planta Med* 2013;79:1516-24. (IF = 2.339, 21)
31. Tovilovic G, Zogovic N, Soskic V, Schrattenholz A, Kostic-Rajacic S, Misirkic-Marjanovic M, Janjetovic K, Vucicevic L, Arsikin K, Harhaji-Trajkovic L, Trajkovic V. Arylpiperazine-mediated activation of Akt protects SH-SY5Y neuroblastoma cells from 6-hydroxydopamine-induced apoptotic and autophagic death. *Neuropharmacology* 2013;72:224-35. (IF = 4.819, 21)
32. Sumarac-Dumanovic M, Jeremic D, Pantovic A, Janjetovic K, Stamenkovic-Pejkovic D, Cvijovic G, Stevanovic D, Micic D, Trajkovic V. Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels. *Immunobiology* 2013;218:1113-8. (IF = 3.180, 22)
33. Tovilovic G, Ristic B, Siljic M, Nikolic V, Kravic-Stevovic T, Dulovic M, Milenkovic M, Knezevic A, Bosnjak M, Bumbasirevic V, Stanojevic M, Trajkovic V. mTOR-independent autophagy counteracts apoptosis in herpes simplex virus type 1-infected U251 glioma cells. *Microbes Infect* 2013;15:615-24. (IF = 2.731, 22)
34. Nesic DM, Stevanovic DM, Stankovic SD, Milosevic VL, Trajkovic V, Starcevic VP, Severs WB. Age-dependent modulation of central ghrelin effects on food intake and lipid metabolism in rats. *Eur J Pharmacol* 2013;710:85-91. (IF = 2.684, 22)
35. Pantic I, Nesic D, Stevanovic D, Starcevic V, Pantic S, Trajkovic V. Effects of ghrelin on the structural complexity of exocrine pancreas tissue architecture. *Microsc Microanal* 2013;19:553-8. (IF = 2.161, 21)
36. Popovic-Kuzmanovic D, Novakovic I, Stojanovich L, Aksentijevich I, Zogovic N, Tovilovic G, Trajkovic V. Increased activity of interleukin-23/interleukin-17 cytokine axis in primary antiphospholipid syndrome. *Immunobiology* 2013;218:186-91. (IF = 3.180, 22)
37. Pantovic A, Krstic A, Janjetovic K, Kocic J, Harhaji-Trajkovic L, Bugarski D, Trajkovic V. Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells. *Bone* 2013;52:524-31. (IF = 4.461, 21)
38. Jokanovi V, olovi B, Dutour Sikiri M, Trajkovi V. A new approach to the drug release kinetics of a discrete system: SiO₂ system obtained by ultrasonic dry spraying. *Ultrason Sonochem* 2013;20:535-45. (IF = 3.816, 21)
39. Trpkovic A, Todorovic-Markovic B, Trajkovic V. Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress. *Arch Toxicol* 2012;86:1809-27. (IF = 5.215, 21)
40. Maksimovi -Ivani D, Mijatovi S, Mirkov I, Stoši -Gruji i S, Miljkovi D, Sabo TJ, Trajkovi V, Kalu erovi GN. Melanoma tumor inhibition by tetrachlorido(O,O'-dibutyl-ethylenediamine-N,N'-di-3-propionate)platinum(IV) complex: in vitro and in vivo investigations. *Metallomics* 2012;4:1155-9. (IF = 4.099, 21)
41. Arsikin K, Kravic-Stevovic T, Jovanovic M, Ristic B, Tovilovic G, Zogovic N, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L. Autophagy-dependent and -independent involvement of AMP-activated protein kinase in 6-hydroxydopamine toxicity to SH-SY5Y neuroblastoma cells. *Biochim Biophys Acta* 2012;1822:1826-36. (IF = 4.910, 21)
42. Markovic ZM, Ristic BZ, Arsikin KM, Klisic DG, Harhaji-Trajkovic LM, Todorovic-Markovic BM, Kepic DP, Kravic-Stevovic TK, Jovanovic SP, Milenkovic MM, Milivojevic DD, Bumbasirevic VZ, Dramicanin MD, Trajkovic VS. Graphene quantum dots as autophagy-inducing photodynamic agents. *Biomaterials* 2012;33:7084-92. (IF = 7.604, 21)
43. Radovic J, Maksimovic-Ivanic D, Timotijevic G, Popadic S, Ramic Z, Trajkovic V, Miljkovic D, Stosic-Grujicic S, Mijatovic S. Cell-type dependent response of melanoma cells to aloe emodin. *Food Chem Toxicol* 2012;50:3181-9. (IF = 3.010, 21)
44. Aloe-emodin inhibits proliferation of adult human keratinocytes in vitro. Popadic D, Savic E, Ramic Z, Djordjevic V, Trajkovic V, Medenica L, Popadic S. *J Cosmet Sci* 2012;63:297-302. (IF = 1.451, 23)

45. Harhaji-Trajkovic L, Arsikin K, Kravic-Stevovic T, Petricevic S, Tovilovic G, Pantovic A, Zogovic N, Ristic B, Janjetovic K, Bumbasirevic V, Trajkovic V. Chloroquine-mediated lysosomal dysfunction enhances the anticancer effect of nutrient deprivation. *Pharm Res* 2012;29:2249-63. (IF = 4.742, 21)
46. Pantic I, Harhaji-Trajkovic L, Pantovic A, Milosevic NT, Trajkovic V. Changes in fractal dimension and lacunarity as early markers of UV-induced apoptosis. *J Theor Biol* 2012;303:87-92. (IF = 2.351, 21)
47. Klionsky DJ, Abdalla FC, Abeliovich H...Trajkovic V...et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012;8:445-544. (IF = 12.042, 21)
48. Misirlic Dencic S, Poljarevic J, Vilimanovich U, Bogdanovic A, Isakovic AJ, Kravic Stevovic T, Dulovic M, Zogovic N, Isakovic AM, Grguric-Sipka S, Bumbasirevic V, Sabo T, Trajkovic V, Markovic I. Cyclohexyl analogues of ethylenediamine dipropanoic acid induce caspase-independent mitochondrial apoptosis in human leukemic cells. *Chem Res Toxicol* 2012;25:931-9. (IF = 3.667, 21)
49. Tovilovic G, Zogovic N, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Janjetovic K, Vucicevic L, Kostic-Rajacic S, Schrattenholz A, Isakovic A, Soskic V, Trajkovic V. Arylpiperazine dopaminergic ligands protect neuroblastoma cells from nitric oxide (NO)-induced mitochondrial damage and apoptosis. *ChemMedChem* 2012;7:495-508. (IF = 2.835, 22)
50. Tadi VM, Jeremic I, Dobric S, Isakovic A, Markovic I, Trajkovic V, Bojovic D, Arsic I. Anti-inflammatory, gastroprotective and cytotoxic effects of *Sideritis scardica* extracts. *Planta Med* 2012;78:415-27. (IF = 2.348, 21)
51. Stevanovic D, Janjetovic K, Misirkic M, Vucicevic L, Sumarac-Dumanovic M, Micic D, Starcevic V, Trajkovic V. Intracerebroventricular administration of metformin inhibits ghrelin-induced hypothalamic AMP-kinase signalling and food intake. *Neuroendocrinology* 2012;96:24-31. (IF = 3.537, 22)
52. Trmcic MV, Matovic RV, Tovilovic GI, Ristic BZ, Trajkovic VS, Ferjancic ZB, Saicic RN. A novel C,D-spirolactone analogue of paclitaxel: autophagy instead of apoptosis as a previously unknown mechanism of cytotoxic action for taxoids. *Org Biomol Chem* 2012;10:4933-42. (IF = 3.568, 21)
53. Misirkic M, Janjetovic K, Vucicevic L, Tovilovic G, Ristic B, Vilimanovich U, Harhaji-Trajkovic L, Sumarac-Dumanovic M, Micic D, Bumbasirevic V, Trajkovic V. Inhibition of AMPK-dependent autophagy enhances in vitro antitumor effect of simvastatin. *Pharmacol Res* 2012;65:111-9. (IF = 4.346, 21)
54. Stevanovic D, Starcevic V, Vilimanovich U, Nesic D, Vucicevic L, Misirkic M, Janjetovic K, Savic E, Popadic D, Sudar E, Micic D, Sumarac-Dumanovic M, Trajkovic V. Immunomodulatory actions of central ghrelin in diet-induced energy imbalance. *Brain Behav Immun* 2012;26:150-8. (IF = 5.612, M21)
55. Tulic C, Lazic M, Savic E, Popadic D, Djukic J, Spasic D, Markovic M, Ramic Z, Mostarica-Stojkovic M, Trajkovic V. The preoperative activity of Th1 and Th17 cytokine axes in prediction of sepsis after radical cystectomy. *Eur Cytokine Netw* 2011;22:169-74. (IF = 1.726, M23)
56. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D, Trajkovic V. In vitro and in vivo anti-melanoma action of metformin. *Eur J Pharmacol* 2011;668:373-82. (IF = 2.516, M22)
57. Savi A, Dulovi M, Poljarevi JM, Misirli -Den i S, Jovanovi M, Bogdanovi A, Trajkovi V, Sabo TJ, Grguri -Šipka S, Markovi I. Synthesis and in vitro anticancer activity of ruthenium-cymene complexes with cyclohexyl-functionalized ethylenediamine-N,N'-diacetate-type ligands. *ChemMedChem* 2011;6:1884-91. (IF = 3.151, M21)
58. Sudar E, Dobutovic B, Soskic S, Mandusic V, Zakula Z, Misirkic M, Vucicevic L, Janjetovic K, Trajkovic V, Mikhailidis DP, Isenovic ER. Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. *J Physiol Biochem* 2011;67:195-204. (IF = 1.711, M23)
59. Markovic ZM, Harhaji-Trajkovic LM, Todorovic-Markovic BM, Kepi DP, Arsikin KM, Jovanovi SP, Pantovic AC, Drami anin MD, Trajkovic VS. In vitro comparison of the photothermal anticancer activity of graphene nanoparticles and carbon nanotubes. *Biomaterials* 2011;32:1121-9. (IF = 7.404, M21)
60. Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. *Eur J Pharmacol* 2011;651:41-50. (IF = 2.516, M22)
61. Vucicevic L, Misirkic M, Kristina J, Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L, Kravic-Stevovic T, Vladimir B, Trajkovic V. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. *Autophagy* 2011;7:40-50. (IF = 7.453, M21)
62. Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S. Metformin: its emerging role in oncology. *Hormones* 2011;10:5-15. (IF = 2.437, M23)
63. Trpkovic A, Todorovic-Markovic B, Kleut D, Misirkic M, Janjetovic K, Vucicevic L, Pantovic A, Jovanovic S, Dramicanin M, Markovic Z, Trajkovic V. Oxidative stress-mediated hemolytic activity of solvent exchange-prepared fullerene (C₆₀) nanoparticles. *Nanotechnology* 2010;21:375102. (IF = 3.652, M21)

64. Lazi JM, Vuci evi L, Grguri -Sipka S, Janjetovi K, Kaluderovi GN, Misirki M, Gruden-Pavlovi M, Popadi D, Paschke R, Trajkovi V, Sabo TJ. Synthesis and in vitro anticancer activity of octahedral platinum(IV) complexes with cyclohexyl-functionalized ethylenediamine-N,N'-diacetate-type ligands. *ChemMedChem* 2010;5:881-9. (IF = 3.306, M21)
65. Djinovi VM, Glodjovi , VV, Vasi GP, Trajkovi V, Klisuri O, Stankovi S, Sabo TJ, Trifunovi SR. Stereospecific ligands and their complexes. IV: Synthesis, characterization and cytotoxicity of novel platinum(IV) complexes with ethylenediamine-N,N'-di-S,S-2-propanoate and halogenido ligands: Crystal structure of s-cis-[Pt(S,S-eddp)Cl₂].4H₂O and uns-cis-[Pt(S,S-eddp)Br₂]. *Polyhedron* 2010;29:1933-8. (IF = 2.034, M22)
66. Krmpot AJ, Janjetovic KD, Misirkic MS, Vucicevic LM, Pantelic DV, Vasiljevic DM, Popadic DM, Jelenkovic BM, Trajkovic VS. Protective effect of autophagy in laser-induced glioma cell death in vitro. *Lasers Surg Med* 2010;42:338-47. (IF = 3.000, M21)
67. Jovanovic SP, Markovic ZM, Kleut DN, Trajkovic V, Babic-Stojic BS, Dramicanin MD, Markovic Todorovic B. Singlet oxygen generation by higher fullerene-based colloids. *J Serb Chem Soc* 2010;75:965-73. (IF = 0.725, M23)
68. Zogovic NS, Nikolic NS, Vranjes-Djuric SD, Harhaji LM, Vucicevic LM, Janjetovic KD, Misirkic MS, Todorovic-Markovic BM, Markovic ZM, Milonjic SK, Trajkovic VS. Opposite effects of nanocrystalline fullerene (C₆₀) on tumour cell growth in vitro and in vivo and a possible role of immunosuppression in the cancer-promoting activity of C₆₀. *Biomaterials* 2009;30:6940-6. (IF = 7.365, M21)
69. Jovanovi SP, Markovi ZM, Kleut DN, Romcevi NZ, Trajkovi VS, Drami anin MD, Todorovi Markovi BM. A novel method for the functionalization of gamma-irradiated single wall carbon nanotubes with DNA. *Nanotechnology* 2009;20:445602. (IF = 3.137, M21)
70. Nikoli N, Vranjes-Djuri S, Jankovi D, Djoki D, Mirkovi M, Bibi N, Trajkovi V. Preparation and biodistribution of radiolabeled fullerene C₆₀ nanocrystals. *Nanotechnology* 2009;20:385102. (IF = 3.137, M21)
71. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumor cells. *J Cell Mol Med* 2009;13: 3644-54. (IF = 5.228, M21)
72. Vucicevic L, Misirkic M, Janjetovic K, Harhaji-Trajkovic L, Prica M, Stevanovic D, Isenovic E, Sudar E, Sumarac-Dumanovic M, Micic D, Trajkovic V. AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. *Biochem Pharmacol* 2009;77:1684-93. (IF = 4.254, M21)
73. Markovic Z, Jovanovic S, Kleut D, Romcevic, N, Jokanovic V, Trajkovic V, Todorovic-Markovic B. Comparative study on modification of single wall carbon nanotubes by sodium dodecylbenzene sulfonate and melamine sulfonate superplasticiser. *Appl Surf Sci* 2009;255:6359-66. (IF = 1.616, M22)
74. Misirkic MS, Todorovic-Markovic BM, Vucicevic LM, Janjetovic KD, Jokanovic VR, Dramicanin MD, Markovic ZM, Trajkovic VS. The protection of cells from nitric oxide-mediated apoptotic death by mechanochemically synthesized fullerene (C₆₀) nanoparticles. *Biomaterials* 2009;30:2319-28. (IF = 7.365, M21)
75. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, Starcevic V, Trajkovic V, Micic D. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. *Int J Obes (Lond)* 2009;33:151-6. (IF = 4.343, M21)
76. Isakovic A, Harhaji L, Dacevic M, Trajkovic V. Adenosine rescues glioma cells from cytokine-induced death by interfering with the signaling network involved in nitric oxide production. *Eur J Pharmacol* 2008;591:106-13. (IF = 2.787, M22)
77. Markovic Z, Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C₆₀). *Biomaterials* 2008;29:3561-73. (IF = 6.646, M21)
78. Harhaji L, Isakovic A, Vucicevic L, Janjetovic K, Misirkic M, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Nikolic Z, Trajkovic V. Modulation of tumor necrosis factor-mediated cell death by fullerenes. *Pharm Res* 2008;25:1365-76. (IF = 4.024, M21)
79. Isakovic A, Jankovic T, Harhaji L, Kostic-Rajacic S, Nikolic Z, Vajs V, Trajkovic V. Antiglioma action of xanthenes from *Gentiana kochiana*: Mechanistic and structure-activity requirements. *Bioorg Med Chem* 2008;16:5683-94. (IF = 3.075, M21)
80. Janjetovic K, Misirkic M, Vucicevic L, Harhaji L, Trajkovic V. Synergistic antiglioma action of hyperthermia and nitric oxide. *Eur J Pharmacol* 2008;583:1-10. (IF = 2.787, M22)
81. Popadic S, Ramic Z, Medenica L, Mostarica Stojkovic M, Trajkovi V, Popadic D. Antiproliferative effect of vitamin A and D analogues on adult human keratinocytes in vitro. *Skin Pharmacol Physiol* 2008;21:227-34. (IF = 2.388, M21)
82. Markovic Z, Todorovic-Markovic B, Kleut D, Nikolic N, Vranjes-Djuric S, Misirkic M, Vucicevic L, Janjetovic K, Isakovic A, Harhaji L, Babic-Stojic B, Dramicanin M, Trajkovic V. The mechanism of cell-

- damaging reactive oxygen generation by colloidal fullerenes. *Biomaterials* 2007;28:5437-48. (IF = 6.262, M21)
83. Vuckovi I, Trajkovi V, Macura S, Tesevi V, Jana kovi P, Milosavljevi S. A novel cytotoxic lignan from *Seseli annuum* L. *Phytother Res* 2007;21:790-2. (IF = 1.430, M23)
 84. Harhaji L, Isakovic A, Raicevic N, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Markovic I, Trajkovic V. Multiple mechanisms underlying the anticancer action of nanocrystalline fullerene. *Eur J Pharmacol* 2007;568:89-98. (IF = 2.376, M22)
 85. Harhaji L, Mijatovic S, Maksimovic-Ivanic D, Popadic D, Isakovic A, Todorovic-Markovic B, Trajkovic V. Aloe emodin inhibits the cytotoxic action of tumor necrosis factor. *Eur J Pharmacol* 2007;568:248-59. (IF = 2.376, M22)
 86. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D, Trajkovic V. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. *Cell Mol Life Sci* 2007;64:1290-302. (IF = 5.239, M21)
 87. Isakovic A, Markovic Z, Nikolic N, Todorovic-Markovic B, Vranjes-Djuric S, Harhaji L, Raicevic N, Romcevic N, Vasiljevic-Radovic D, Dramicanin M, Trajkovic V. Inactivation of nanocrystalline C₆₀ cytotoxicity by gamma-irradiation. *Biomaterials* 2006;27:5049-58. (IF = 5.196, M21)
 88. Ferjancic Z, Matovic R, Cekovic Z, Jiang Y, Snyder JP, Trajkovic V, Saicic RN. Synthesis, biology, and modeling of a C-4 carbonyl C,D-seco-taxoid. *Tetrahedron* 2006;62:8503-14. (IF = 2.817, M22)
 89. Popadic S, Popadic D, Ramic Z, Mostarica Stojkovic M, Trajkovic V, Milinkovic M, Medenica L. Chloramphenicol induces in vitro growth arrest and apoptosis of human keratinocytes. *Cell Biol Toxicol* 2006;22:371-9. (IF = 1.400, M23)
 90. Isakovic A, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Mirkovic M, Dramicanin M, Harhaji L, Raicevic N, Nikolic Z, Trajkovic V. Distinct cytotoxic mechanisms of pristine versus hydroxylated fullerene. *Toxicol Sci* 2006;91:173-83. (IF = 3.598, M21)
 91. Harhaji L, Popadic D, Miljkovic D, Cvetkovic I, Isakovic A, Trajkovic V. Acidosis affects tumor cell survival through modulation of nitric oxide release. *Free Radic Biol Med* 2006;40:226-35. (IF = 5.440, M21)
 92. Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S, Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. *Cell Mol Life Sci* 2005;62:2658-68. (IF = 4.582, M21)
 93. Kaludjerovic GN, Miljkovic D, Momcilovic M, DjinoVIC VM, Mostarica Stojkovic M, Sabo TJ, Trajkovic V. Novel platinum(IV) complexes induce rapid tumor cell death in vitro. *Int J Cancer* 2005;116:479-86. (IF = 4.700, M21)
 94. Markovic M, Knezevic N, Momcilovic M, Grguric-Sipka S, Harhaji L, Trajkovic V, Mostarica Stojkovic M, Sabo T, Miljkovic D. [Pt(HPxSC)Cl(3)], a novel platinum(IV) compound with anticancer properties. *Eur J Pharmacol* 2005;517:28-34. (IF = 2.477, M22)
 95. Mijatovic S, Maksimovic-Ivanic D, Radovic J, Miljkovic D, Kaludjerovic GN, Sabo TJ, Trajkovic V. Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin. *Cell Mol Life Sci* 2005;62:1275-82. (IF = 4.582, M21)
 96. Singh G, Singh B, Trajkovic V, Sharma P. *Mycobacterium tuberculosis* 6 kDa early secreted antigenic target stimulates activation of J774 macrophages. *Immunol Lett* 2005;98:180-8. (IF = 2.301, M22)
 97. Raicevic N, Mladenovic A, Perovic M, Harhaji L, Miljkovic D, Trajkovic V. Iron protects astrocytes from 6-hydroxydopamine toxicity. *Neuropharmacology* 2005;48:720-31. (IF = 3.637, M21)
 98. Mijatovic S, Maksimovic-Ivanic D, Radovic J, Miljkovic Dj, Harhaji Lj, Vuckovic O, Stosic-Grujicic S, Mostarica Stojkovic M, Trajkovic V. Anti-glioma action of aloe emodin: the role of ERK inhibition. *Cell Mol Life Sci* 2005;62:589-98. (IF = 4.582, M21)
 99. Raicevic N, Mladenovic A, Perovic M, Miljkovic D, Trajkovic V. The mechanisms of 6-hydroxydopamine-induced astrocyte death. *Ann NY Acad Sci* 2005;1048:400-5. (IF = 1.971, M21)
 100. DjinoVIC V, Momcilovic M, Grguric-Sipka S, Trajkovic V, Mostarica Stojkovic M, Miljkovic D, Sabo T. Novel ruthenium complex K₂[Ru(dmgly)Cl₄]x2H₂O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. *J Inorg Biochem* 2004;98:2168-73. (IF = 2.225, M21)
 101. Miljkovic Dj, Markovic M, Trajkovic V. Inducible nitric oxide synthase inhibition by mycophenolic acid. *Mini Rev Med Chem* 2004;4:741-6. (IF = 3.163, M21)
 102. Trajkovic V, Vuckovic O, Stosic-Grujicic S, Miljkovic D, Popadic D, Markovic M, Bumbasirevic V, Backovic A, Cvetkovic I, Harhaji L, Ramic Z, Mostarica Stojkovic M. Astrocyte-induced regulatory T cells mitigate CNS autoimmunity. *Glia* 2004;47:168-79. (IF = 4.781, M21)
 103. Mijatovic S, Maksimovic-Ivanic D, Radovic J, Popadic D, Momcilovic M, Harhaji L, Miljkovic D, Trajkovic V. Aloe-emodin prevents cytokine-induced tumor cell death: the inhibition of auto-toxic nitric oxide release as a potential mechanism. *Cell Mol Life Sci* 2004;61:1805-15. (IF = 4.812, M21)
 104. Harhaji L, Vuckovic O, Miljkovic D, Stosic-Grujicic S, Trajkovic V. Iron down-regulates macrophage anti-tumour activity by blocking nitric oxide production. *Clin Exp Immunol* 2004;137:109-16. (IF = 2.518, M22)

105. Stosic-Grujicic SD, Miljkovic DM, Cvetkovic ID, Maksimovic-Ivanic DD, Trajkovic V. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. *J Autoimmun* 2004;22:267-76. (IF = 1.917, M23)
106. Cvetkovic I, Miljkovic D, Vuckovic O, Harhaji L, Nikolic Z, Trajkovic V, Mostarica Stojkovic M. Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF- κ B. *Cell Mol Life Sci* 2004;61:1167-75. (IF = 4.812, M21)
107. Trajkovic V, Sweet MJ, Xu D. T1/ST2-an IL-1 receptor-like modulator of immune responses. *Cytokine Growth Factor Rev* 2004;15:87-95. (IF = 9.926, M21)
108. Trajkovic V, Natarajan K, Sharma P. Immunomodulatory action of mycobacterial secretory proteins. *Microbes Infect* 2004;6:513-9. (IF = 3.753, M21)
109. Miljkovic D, Cvetkovic I, Sajic M, Vuckovic O, Harhaji L, Markovic M, Trajkovic V. 5-Aza-2'-deoxycytidine and paclitaxel inhibit inducible nitric oxide synthase activation in fibrosarcoma cells. *Eur J Pharmacol* 2004;485:81-8. (IF = 2.432, M22)
110. Cvetkovic I, Popadic D, Vuckovic O, Harhaji Lj, Miljkovic Dj, Trajkovic V. 5-Aza-2'-deoxycytidine stimulates inducible nitric oxide synthase induction in C6 astrocytoma cells. *Brain Res* 2004;998:83-90. (IF = 2.389, M22)
111. Miljkovic D, Trajkovic V. Inducible nitric oxide synthase activation by interleukin-17. *Cytokine Growth Factor Rev* 2004;15:21-32. (IF = 9.926, M21)
112. Singh B, Singh G, Trajkovic V, Sharma P. Intracellular expression of Mycobacterium tuberculosis-specific 10-kDa antigen down-regulates macrophage B7.1 expression and nitric oxide release. *Clin Exp Immunol* 2003;134:70-7. (IF = 2.347, M22)
113. Markovic M, Trajkovic V, Drulovic J, Mesaros S, Stojavljevic N, Dujmovic I, Mostarica Stojkovic M. Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients. *J Neurol Sci* 2003;211:67-73. (IF = 2.140, M22)
114. Miljkovic Dj, Cvetkovic I, Stosic-Grujicic S, Trajkovic V. Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts. *Clin Exp Immunol* 2003;132:239-46. (IF = 2.347, M22)
115. Miljkovic Dj, Cvetkovic I, Vuckovic O, Stosic-Grujicic S, Mostarica Stojkovic M, Trajkovic V. The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells. *Cell Mol Life Sci* 2003;60:518-25. (IF = 4.995, M21)
116. Trajkovic V, Singh G, Singh B, Singh S, Sharma P. Effect of Mycobacterium tuberculosis-specific 10-kilodalton antigen on macrophage release of tumor necrosis factor alpha and nitric oxide. *Infect Immun* 2002;70:6558-66. (IF = 4.039, M21)
117. Stosic-Grujicic S, Maksimovic-Ivanic D, Miljkovic D, Trajkovic V, Lukic M, Mostarica Stojkovic M. Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue. *Transplant Proc* 2002;34:2955-7. (IF = 0.478, M23)
118. Miljkovic D, Samardzic T, Cvetkovic I, Mostarica Stojkovic M, Trajkovic V. Mycophenolic acid downregulates inducible nitric oxide synthase induction in astrocytes. *Glia* 2002;39:247-55. (IF = 4.600, M21)
119. Miljkovic Dj, Samardzic T, Drakulic D, Stosic-Grujicic S, Trajkovic V. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. *Cytokine* 2002;19:181-6. (IF = 2.374, M22)
120. Maksimovic-Ivanic D, Trajkovic V, Miljkovic DJ, Mostarica Stojkovic M, Stosic-Grujicic S. Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. *Clin Exp Immunol* 2002;129:214-23. (IF = 2.305, M22)
121. Miljkovic Dj, Drulovic J, Trajkovic V, Mesaros S, Dujmovic I, Maksimovic D, Samardzic T, Stojavljevic N, Levic Z, Mostarica Stojkovic M. Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients. *Eur J Neurol* 2002;9:413-8. (IF = 1.565, M21)
122. Miljkovic D, Markovic M, Bogdanovic N, Mostarica Stojkovic M, Trajkovic V. Necrotic tumor cells oppositely affect nitric oxide production in tumor cell lines and macrophages. *Cell Immunol* 2002;215:72-7. (IF = 1.988, M22)
123. Trajkovic V, Stosic-Grujicic S, Samardzic T, Markovic M, Miljkovic D, Ramic Z, Mostarica Stojkovic M. Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. *J Neuroimmunol* 2001;119:183-91. (IF = 3.342, M21)
124. Trajkovic V. Modulation of inducible nitric oxide synthase activation by immunosuppressive drugs. *Curr Drug Metab* 2001;2:315-29. (IF = 0.600, M23)
125. Trajkovic V, Markovic M, Samardzic T, Miljkovic DJ, Popadic D, Mostarica Stojkovic M. Amphotericin B potentiates the activation of inducible nitric oxide synthase and causes nitric oxide-dependent mitochondrial dysfunction in cytokine-treated rodent astrocytes. *Glia* 2001;35:180-8. (IF = 4.193, M21)

126. Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic V, Campbell CC, Xu D, Liew FY. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. *J Immunol* 2001;166:6633-9. (IF = 7.065, M21)
127. Stepanovi S, Vukovic D, Trajkovi V, Samardzi T, Cupi M, Svabi -Vlahovi M. Possible virulence factors of *Staphylococcus sciuri*. *FEMS Microbiol Lett* 2001;199:47-53. (IF = 1.806, M22)
128. Samardzic T, Jankovic V, Stosic-Grujicic S, Popadic D, Trajkovic V. Pentoxifylline inhibits the synthesis and IFN- γ -inducing activity of IL-18. *Clin Exp Immunol* 2001;124:274-81. (IF = 2.716, M22)
129. Samardzic T, Stosic-Grujicic S, Raicevic N, Trajkovic V. Tumor cell-specific inhibition of inducible nitric oxide synthase activation by tiazofurin. *Int Immunopharmacol* 2001;1:795-802. (IF = 1.655, M22)
130. Samardzic T, Jankovic V, Stosic-Grujicic S, Trajkovic V. STAT1 is required for iNOS activation, but not IL-6 production in murine fibroblasts. *Cytokine* 2001;13:179-82. (IF = 1.992, M22)
131. Stosi -Grujici S, Maksimovi D, Badovinac V, Samardzi T, Trajkovi V, Luki M, Mostarica Stojkovi M. Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production. *J Autoimmun* 2001;16:47-58. (IF = 2.745, M21)
132. Miljkovic D, Samardzic T, Mostarica Stojkovic M, Stosic-Grujicic S, Popadic D, Trajkovic V. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes. *Brain Res* 2001;889:331-8. (IF = 2.489, M22)
133. Trajkovic V, Samardzic T, Stosic-Grujicic S, Ramic Z, Mostarica Stojkovic M. Muramyl dipeptide potentiates cytokine-induced activation of inducible nitric oxide synthase in rat astrocytes. *Brain Res* 2000;883:157-63. (IF = 2.526, M22)
134. Xu D, Trajkovic V, Hunter D, Leung BP, Schulz K, Gracie JA, McInnes IB, Liew FY. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. *Eur J Immunol* 2000;30:3147-56. (IF = 4.990, M21)
135. Badovinac V, Trajkovic V, Mostarica-Stojkovic M. Nitric oxide promotes growth and major histocompatibility complex-unrestricted cytotoxicity of interleukin-2-activated rat lymphocytes. *Scand J Immunol* 2000;52:62-70. (IF = 1.777, M23)
136. Trajkovic V, Stepanovic S, Samardzic T, Jankovic V, Badovinac V, Mostarica Stojkovic M. *Cryptococcus neoformans* neutralizes macrophage and astrocyte derived nitric oxide without interfering with inducible nitric oxide synthase induction or catalytic activity - possible involvement of nitric oxide consumption. *Scand J Immunol* 2000;51:384-91. (IF = 1.777, M23)
137. Samardzic T, Stosic-Grujicic S, Maksimovic D, Jankovic V, Trajkovic V. Differential regulation of nitric oxide production by increase of intracellular cAMP in murine primary fibroblasts and L929 fibrosarcoma cell line. *Immunol Lett* 2000;71:149-55. (IF = 1.546, M23)
138. Jankovic V, Samardzic T, Stosic-Grujicic S, Popadic D, Trajkovic V. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide. *Cell Immunol* 2000;199:73-80. (IF = 2.206, M22)
139. Trajkovi V, Badovinac V, Jankovi V, Samardzic T, Maksimovi D, Popadi D. Cyclosporin A suppresses the induction of nitric oxide synthesis in interferon-gamma-treated L929 fibroblasts. *Scand J Immunol* 1999;49:126-30. (IF = 1.740, M23)
140. Trajkovi V, Badovinac V, Jankovi V, Mostarica Stojkovi M. Cyclosporin A inhibits activation of inducible nitric oxide synthase in C6 glioma cell line. *Brain Res* 1999;816:92-8. (IF = 2.302, M22)
141. Badovinac V, Boggiano C, Trajkovi V, Frey AB, Vujanovi NL, Gold DP, Mostarica-Stojkovi M, Vukmanovi S. Rat NKR-P1+ CD3+ T cells: selective proliferation in interleukin-2, diverse T-cell-receptor-Vbeta repertoire and polarized interferon-gamma expression. *Immunology* 1998;95:117-25. (IF = 2.752, M21)
142. Stosi -Grujici S, Trajkovi V, Badovinac V, Mostarica Stojkovi M. Pentoxifylline potentiates nitric oxide production and growth suppression in interferon-gamma-treated L929 fibroblasts. *Cell Immunol* 1998;184:105-11. (IF = 2.125, M22)
143. Trajkovi V, Badovinac V, Popadi D, Hadzi O, Stojkovi MM. Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression. *Immunology* 1997;92:402-6. (IF = 2.752, M21)

Izvodi sa me unarodnog skupa:

1. Volarevic V, Paunovic V, Markovic Z, Markovic BS, Marjanovic MM, Markovic BT, Bojic S, Vucicevic L, Jovanovic S, Arsenijevic N, Holclajtner-Antunovic I, Milosavljevic M, Dramicanin M, Stevovic TK, Ciric D, Lukic ML, Trajkovic V. Graphene quantum dots attenuate concanavalin A-induced hepatitis. 50th International Liver Congress of the European Association for the Study of the Liver, Vienna, Austria, 2015. *J Hepatol* 2015;62, Supplement 2:S483-S484, Meeting Abstract: P0457.
2. Dulovic M, Jovanovic M, Harhaji-Trajkovic L, Stefanis L, Xilouri M, Kostic V, Trajkovic V, Markovic I. The protective role of AMPK and Akt in neurotoxicity caused by intracellular and extracellular alpha-synuclein accumulation in vitro. 27th Congress of the European College of Neuropsychopharmacology

- (ECNP), Berlin, Germany, 2014. Eur Neuropsychopharmacol 2014;24, Supplement 2:S641-S642, Meeting Abstract: P.5.c.001.
3. Petronijevic N, Jevtic G, Nikolic T, Mircic A, Stojkovic T, Trajkovic V, Markovic I, Velimirovic M, Trbovich A, Radonjic N. Mitochondrial impairment, apoptosis and autophagy in the rat brain as immediate and long term effects of perinatal phencyclidine treatment. 27th ECNP Congress, Berlin, Germany, 2014. Eur Neuropsychopharmacol 2014;24, Supplement 2:S269-S270, Meeting Abstract: P.1.g.112.
 4. Popovic M, Stanojevic Z, Tosic J, Isakovic A, Paunovic V, Petricevic S, Martinovic T, Ciric D, Trajkovic V. Protective effect of arylpiperazine-based dopaminergic ligand treatment in experimental autoimmune encephalomyelitis. 27th ECNP Congress, Berlin, Germany, 2014. Eur Neuropsychopharmacol 2014;24, Supplement 2:S199-S199, Meeting Abstract: P.1.f.008.
 5. Stanojevic Z, Tosic J, Popovic M, Petricevic S, Trajkovic V, Nedeljkovic N, Jovanovic M, Isakovic A. The protective role of arylpiperazine in neuroinflammation 27th ECNP Congress, Berlin, Germany, 2014. Eur Neuropsychopharmacol 2014;24, Supplement 2:S248-S248, Meeting Abstract: P.1.g.077.
 6. Markovic I, Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Trajkovic V, Kostic VS. The neuroprotective role of AMP-activated protein kinase against the toxicity of intracellular and extracellular alpha-synuclein in vitro. 18th International Congress of Parkinson's Disease and Movement Disorders, Stockholm, Sweden, 2014. Mov Dis 2014;29, Supplement 1:S23-S23, Meeting Abstract: 62.
 7. Volarevic V, Milovanovic M, Simovic Markovic B, Stojanovic M, Misirkic M, Vucicevic L, Trajkovic V, Arsenijevic N, Lukic ML. Metformin aggravates Con A induced liver injury. European Congress of Immunology, Glasgow, Scotland, 2012. Immunology 2012;137, Special Issue Supplement 1:505-505.
 8. Markovic I, Dulovic M, Jovanovic M, Harhaji-Trajkovic L, Tovilovic G, Xilouri M, Stefanis L, Trajkovic V, Kostic VS. The protective role of AMPK and Akt signalling in alpha-synuclein neurotoxicity in vitro. 16th International Congress of Parkinson's Disease and Movement Disorders, Dublin, Ireland, 2012. Mov Dis 2012;27, Supplement 1:S489-S490, Meeting Abstract: 1497.
 9. Petronijevic N, Nikolic T, Radonjic N, Vilimanovich U, Trajkovic V, Bumbasirevic V. Decreased neuregulin-1 in the cortex of rat pups as immediate effect of perinatal phencyclidine treatment. 23rd Congress Meeting of European-College-of-Neuropsychopharmacology, Amsterdam, Netherlands, 2010. Eur Neuropsychopharmacol 2010;20, Supplement 3:S271-S272.
 10. Micic D, Sumarac-Dumanovic M, Stamenkovic-Pejkovic D, Simic M, Cvijovic G, Zoric S, Kendereski A, Stevanovic D, Jorga J, Trajkovic V. The effect of weight loss on inflammatory adipocytokine levels and insulin sensitivity in obese women. 16th European Congress on Obesity Geneva, Switzerland, 2008. Int J Obes 2008;32, Supplement 1:S62-S62.
 11. Sumarac-Dumanovic M, Micic D, Simic M, Stevanovic D, Stamenkovic-Pejkovic D, Jorga J, Cvijovic G, Zoric S, Kendereski A, Trajkovic V. Correlation between adipocytokines and IL-17, IL-23 and MIF in obese women. 16th European Congress on Obesity, Switzerland, 2008. Int J Obes 2008;32, Supplement 1:S58-S58.
 12. Sumarac-Dumanovic M, Micic D, Trajkovic V, Stevanovic D, Jorga J, Georgiev M, Stamenkovic-Pejkovic D, Kendereski A, Cvijovic G, Zoric S. Macrophage migration inhibitory factor (MIF), adipocytokines and insulin sensitivity in severe obese women with normal and impaired glucose tolerance. 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, Netherlands, 2007. Diabetologia 2007;50, Supplement 1:S259-S259, Meeting Abstract: 0627.
 13. Markovic M, Vuckovic O, Trajkovic V, Stosic-Grujicic S, Ramic Z, Mostarica Stojkovic M. Astrocyte-induced regulatory T cells suppress EAE in DA rats. 7th International Congress of the International Society of Neuroimmunology, Venice, Italy, 2004. J Neuroimmunol 2004;154, Special Issue:80-80, Meeting Abstract: 258.
 14. Trajkovic V, Vuckovic O, Popadic D, Markovic M, Miljkovic D, Stosic-Grujicic S, Ramic Z, Mostarica Stojkovic M. Mechanisms responsible for astrocyte-induced development of regulatory T cells. 7th International Congress of the International-Society-of-Neuroimmunology, Venice, Italy, 2004. J Neuroimmunol 2004;154, Special Issue:122-122, Meeting Abstract: 410.
 15. Maksimovic-Ivanic D, Mijatovic S, Radovic J, Popadic D, Miljkovic D, Stosic-Grujicic S, Mostarica Stojkovic M, Trajkovic V. Aloe-emodin down-regulates NO production in glioma cells through inhibition of IRF-1 and ERK activation 7th International Congress of the International Society of Neuroimmunology, Venice, Italy, 2004. J Neuroimmunol 2004;154, Special Issue:179-179, Meeting Abstract: 594.
 16. Mijatovic S, Maksimovic-Ivanic D, Radovic J, Miljkovic D, Harhaji L, Stosic-Grujicic S, Stojkovic MM, Trajkovic V. Aloe-emodin modulates nitric oxide production and glioma cell survival in macrophage-glioma cell cocultures. 7th International Congress of the International-Society-of-Neuroimmunology, Venice, Italy, 2004. J Neuroimmunol 2004;154, Special Issue:180-180, Meeting Abstract: 595.

Poglavlja u udžbenicima, praktikumima:

- Trajkovi V. Osnovna imunologija (II, III, IV i V izdanje, prevod). Abbas A., Lichtman A.H., Pillai S. Data Status, Beograd, 2016. (V izdanje).

- Trajkovi V. Radna sveska za praktičnu nastavu iz mikrobiologije i imunologije, ured. Rami Z., Medicinski fakultet Univerziteta u Beogradu, 2005-2011.
- Trajkovi V. Priručnik za nastavu iz imunologije, ured. Rami Z., Medicinski fakultet Univerziteta u Beogradu, 2012-2016.

Poglavlja u knjigama:

- Trajkovi V, Markovi Z. Nanomedicina: stanje i perspektive, u Biomaterijali, ured. Rakovi D, Uskokovi D, Institut tehničkih nauka SANU, Beograd, 2009.

b) Rukovođenje ili učestvovanje na projektima

- 1998-2000. saradnik na realizaciji projekta Ministarstva za nauku Republike Srbije „Imunoregulatorni i efektorski mehanizmi u imunopatološkim poremećajima i infekciji“, rukovodilac projekta prof. dr Marija Mostarica Stojković
- 2001-2005. saradnik na realizaciji projekata Ministarstva za nauku Republike Srbije br. 2020 („Efektorski i regulatorni mehanizmi u eksperimentalno izazvanim autoimunskim oštećenjima CNS-a“, rukovodilac prof. dr Marija Mostarica Stojković) i br. 1664 („Elijska i molekulska osnova modulacije imunskih poremećaja“, rukovodilac dr Stanislava Stošić-Grujić), u okviru kojih je rukovodio zadacima „Analiza astrocita in vitro“ (2020) i „Kontrola rasta tumorskih elija“ (1664)
- 2005-2010. rukovodilac projekta „Citotoksični, citoprotektivni i imunomodulatorni efekti nanoestrica“ (br. 145073) Ministarstva nauke i tehnološkog razvoja Republike Srbije
- 2011-2017. rukovodilac projekta "Modulacija signalnih puteva koji kontrolišu intracelularni energetske balans u terapiji tumora i neuro-imuno-endokrinih poremećaja" (br. 41025) Ministarstva prosvete, nauke i tehnološkog razvoja Republike Srbije

c) Citiranost

6159 heterocitata, *h*-index bez autocitata = 32 (Scopus, 06.09.2017.)

d) Organizovanje naučnih sastanaka i simpozijuma

e) Druga dostignuća (recenzije, recenzije u časopisima)

Prof. dr Vladimir Trajković je bio recenzent za više od 100 biomedicinskih i multidisciplinarnih časopisa (Nature Nanotechnology, ACS Nano, Autophagy, Biochemical Pharmacology, Molecular and Cellular Biology, Biochimica et Biophysica Acta, Cell Death and Disease, Small, Scientific Reports, International Journal of Obesity, Journal of American Chemical Society, Journal of Infectious Diseases, Journal of Neuroscience Research, BMC Cancer i dr.), kao i za projekte Ministarstva za nauku i tehnologiju Republike Srbije i različitih međunarodnih naučnih fondacija (National Science Foundation – USA, Samantha Dickson Brain Tumour Trust – UK, La Marato Foundation - Spain).

F. OCENA O REZULTATIMA NAUČNOG ISTRAŽIVANJA KOG RADA

Dr Vladimir Trajković je autor ili koautor 143 rada štampana u celini u časopisima sa JCR liste. Jedini ili prvi autor je u 12, nosilac rada u 82 rada, a saradnik u 49 radova. Od poslednjeg izbora objavio je 54 rada, od toga 34 kao nosilac rada i 20 kao saradnik. Pored toga, dr Vladimir Trajković je autor 16 radova (8 od poslednjeg izbora) štampanih u izvodu u zbornicima međunarodnih skupova.

Teme naučnih radova dr Trajković a od poslednjeg izbora mogu se svrstati u tri međusobno povezane celine: 1) Uloga citokina u fiziološkom i patološkom imunskom odgovoru, 2) Uloga autofagije i signalnih puteva koji kontrolišu intracelularni energetske balans (AMPK/Akt/mTOR) u elijskoj smrti, diferencijaciji, neuro-imuno-endokrinim interakcijama i infekciji, i 3) Primena nanoestrica u terapiji tumora, imunoloških i infektivnih bolesti.

U okviru prve celine, prvi put je pokazana sposobnost proinflatornog citokina interleukina-17 da stimuliše produkciju citotoksičnog slobodnog radikala azot monoksida u astrocitima, endotelnim elijama i beta elijama pankreasa (ref. 92, 115, 122), što je ukazalo na mehanizam destruktivne ulogu ovog citokina u zapaljenju i autoimunosti. Takođe je 2009. godine prvi put pokazano da je koncentracija interleukina-17 povišena kod gojaznih osoba (ref. 75), a kasnije studije drugih autora su potvrdile njegovu ulogu u metaboličkom sindromu i gojaznosti. U studiji iz 2013. godine pokazana je pojačana aktivnost IL-23/IL-17 citokinske osovine u antifosfolipidnom sindromu (ref. 36). Dr Trajković je bio član istraživačkog tima Univerziteta u Glazgovu koji je prvi otkrio ključnu ulogu interleukina-18 u indukciji T helper 2 odgovora kod genetski predisponiranih jedinki (ref. 134). Takođe je zajedno sa istraživačima Internacionalnog centra za genetski inženjering i biotehnologiju iz Nju Delhija prvi pokazao sposobnost CFP-10 proteina *M. tuberculosis* da inhibira funkciju makrofaga (ref. 112, 116), što je jedan od bitnih mehanizama supresije imunskog odgovora u tuberkulozi.

U okviru druge celine, nedavno nakon što su epidemiološke studije ukazale na povezanost terapije metforminom i niže uestalosti tumora kod bolesnika sa dijabetesom tipa 2, istraživa ka grupa prof. dr Vladimira Trajkovi a je 2007. godine me u prvim objavila rezultate koji su doprineli rasvetljavanju molekularnih mehanizama i uloge adenozin monofosfatom aktivirane protein kinaze (AMPK) u anti-tumorskom dejstvu ovog poznatog anti-hiperglikemijskog leka (ref. 86). Danas se metformin testira u mnogim klini kim studijama za terapiju i prevenciju tumora. Dr Vladimir Trajkovi je sa saradnicima 2009. godine prvi put pokazano da inhibicija autofagije, procesa programirane intracelularne proteolize indukovane aktivacijom AMPK, poja ava anti-tumorsko dejstvo najpoznatijeg hemioterapeutika cisplatina (ref. 71), što je zajedno sa sli nim radovima poslužio kao osnova za klini ke studije u kojima se danas ispituju inhibitori autofagije kao dodatak klasi noj hemioterapiji. Ovaj koncept podržavaju i kasniji radovi prof. dr Vladimira Trajkovi a i saradnika, u kojima je pokazano da inhibicija u autofagije poja ava antitumorsku aktivnost citarabina, statina, ribavirina i dorzomorfina (ref. 3, 12, 25, 53, 61). Tako e je pokazano da farmakološki inhibitori AMPK i autofagije ostvaruju anti-tumorsko dejstvo i molekularnim mehanizmima koji ne zavise od supresije AMPK i autofagije (ref. 45, 61), što ima bitne implikacije za primenu ovih lekova u hemioterapiji. U tom kontekstu naro ito je zna ajan rad iz 2016. godine u kome je prvi put opisano selektivno sinergisti ko in vitro i in vivo antitumorsko dejstvo lizozomalnih inhibitora i inhibitora glikolize, koje zavisi od interferencije sa produkcijom energije u mitohondrijama tumorskih elija i predstavlja osnovu za nove pristupe u terapiji tumora (ref. 5). Radovi dr Trajkovi a su prvi pokazali protektivno dejstvo AMPK u neurotoksi nosti izazvanoj intracelularnom akumulacijom alfa-sinukleina (ref. 28), kao i neuroprotektivno dejstvo autofagije u terapiji atipi nim antipsihotikom olanzapinom (ref. 18), ime su doprineli rasvetljavanju molekularnih mehanizama neurodegeneracije u Parkinsonovoj bolesti i terapiji shizofrenije. U radovima dr Trajkovi a je prvi put pokazana kompleksna interakcija AMPK/Akt/mTOR signalnog sistema i autofagije u diferencijaciji mezenhimalnih mati nih elija u osteoblaste (ref. 37), kao i elija neuroblastoma u neurone (ref. 15), što je veoma bitno za oblast regenerativne medicine i kancerogeneze. Prvi put je demonstrirana i sposobnost gastri nog hormona grelina da aktivacijom AMPK u hipotalamusu moduliše inflamaciju izazvanu energetske disbalansom (ref. 54), kao i paradoksalna sposobnost metformina da smanji unos hrane inhibicijom hipotalami ne AMPK (ref. 51), što je vrlo zna ajno za metaboli ke efekte ovog leka. Tako e je pokazano da metformin delimi no poništava smanjenje ekspresija gena koji regulišu autofagiju u endometrijalnom tkivu žena sa policisti nim sindromom jajnika (ref. 2), što bi mogao da bude jedan od mehanizama povoljnog dejstva metformina u ovom metaboli kom poreme aju. Rezultati istraživanja prof. dr Vladimira Trajkovi a su prvi put ukazali na mogu nost da bi terapijsko dejstvo metformina u dijabetesu tipa II moglo bar delimi no da bude rezultat smanjenje produkcije IL-17 (ref. 32), ali i da indukcija autofagije metforminom poja ava destruktivnu inflamaciju u mišjem modelu fulminantnog hepatitisa (ref. 16), što ukazuje na kompleksnu ulogu AMPK/mTOR signalnog sistema i autofagije u regulaciji imunskog odgovora. Kona no, pokazana je uloga autofagije u prevenciji apoptoze uzrokovane HSV-1 infekcijom (ref. 33) i predloženi su modeli za interferenciju autofagije sa progresijom virusne infekcije (ref. 21).

U okviru tre e celine prvi put su ispitani molekularni mehanizmi toksi nog, citoprotektivnog, antitumorskog i imunosupresivnog dejstva fullerenskih (C₆₀) nano estica (ref. 39, 63, 68, 74, 77, 78, 82, 84, 90), a pokazano je i da grafenske nano estice pobu ene svetloš u odgovaraju e talasne dužine mogu da ubiju tumorske elije hipertermijom ili produkcijom reaktivnih oblika kiseonika (ref. 42, 59). Tako e, prvi put je pokazano da grafenske kvantne ta ke imaju selektivno fotodinami ko antibakterijsko dejstvo (ref. 24), kao i protektivno dejstvo u autoimunskom hepatitisu (ref. 19), što ukazuje na mogu nost njihove upotrebe u terapiji infekcije i inflamacije. Na osnovu ovih rezultata prof. dr Vladimir Trajkovi je zajedno sa saradnicima iz inostranstva predložio model interakcije nano estica i elija u kome klju nu ulogu ima mTOR signalni put (ref. 8).

Posebno treba ista i multidisciplinarnu i translacionu prirodu istraživanja dr Trajkovi a, u okviru kojih se najsavremenije metode celularne i molekularne biologije (imunoblot, real-time PCR, proto na citofluorimetrija, elektronska i konfokalna mikroskopija, RNK interferencija) koriste u relevantnim animalnim modelima i analizi klini kih uzoraka u cilju otkrivanja molekularnih mehanizama fizioloških i patoloških procesa, kao i novih terapijskih pristupa. Treba i naglasiti da je laboratorija dr Trajkovi a me u prvim u Srbiji po ela da se bavi nanomedicinom i nanotoksikologijom, kao i da trenutno jedina u Srbiji sistematski prou ava autofagiju, proces programirane digestije intracelularnog sadržaja, koji ima važnu ulogu u regulaciji elijske smrti, metabolizma, imunskog odgovora i mnogih drugih fizioloških i patoloških procesa. Iz pregleda objavljenih rezultata nau nog rada i prate ih aktivnosti može se zaklju iti da je Vladimir Trajkovi , kao istraživa u oblasti imunologije i molekularne biologije/farmakologije tumora, sposoban da samostalno i kriti ki pristupi istraživanju i rešavanju nau nih problema. U potpunosti vlada metodologijom istraživanja i savremenim istraživa kim tehnikama, ime u estvuje u rešavanju problema savremene nauke. Treba napomenuti i njegov smisao za timski rad, kao i rukovo enje istraživanjima u okviru grupe istraživa a razli itog profila, kao i izuzetnu informisanost o najnovijim nau nim dostignu ima u oblasti kojom se bavi. Svojim istraživanjima on doprinosi fundamentalnim saznanjima u oblasti imunologije i molekularne biologije/farmakologije tumora, koja ujedno mogu imati i prakti ni, klini ki zna aj.

G. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE

IZBORNI USLOVI ZA IZBOR U NASTAVNIKA ZVANJA

1) Za stručno-profesionalni doprinos:

1.1. Angažovanost u sprovođenju složenih dijagnostičkih, terapijskih i preventivnih procedura: Prof. dr Vladimir Trajković aktivno učestvuje u obavljanje zdravstvene delatnosti Instituta za mikrobiologiju i imunologiju u okviru imunološke dijagnostike.

2) Za doprinos akademskoj i široj zajednici:

2.1. Značajno stručno, nacionalno ili međunarodno priznanje za naučnu ili stručnu delatnost: Prof. dr Vladimir Trajković je dobitnik nagrade za naučno-istraživački rad Medicinskog fakulteta Univerziteta u Beogradu (2005. god.) i nagrade Srpske akademije nauka i umetnosti za naučni rad iz oblasti biomedicine (2013. god.).

2.2. Članstvo u stručnim ili naučnim asocijacijama u koje se član bira ili koje imaju ograničen broj članova: Prof. dr Vladimir Trajković je član Društva imunologa Srbije.

2.4. Uređivanje časopisa ili monografija priznatih od strane resornog ministarstva za nauku: Prof. dr Vladimir Trajković je član uređivačkog odbora časopisa Biomaterials (impakt faktor 8.402, M21) i PLoS One (impakt faktor 2.806, M21).

3) Za saradnju sa drugim visokoškolskim, naučno-istraživačkim ustanovama u zemlji i inostranstvu - mobilnost:

3.1. Predavanja po pozivu i plenarna predavanja:

- IV Balkanski kongres imunologa, Istanbul, Turska (2004): plenarno predavanje "Astrocyte-induced regulatory T cells mitigate CNS autoimmunity" i predsedavanje sesijom "Immune Regulation".

- Konferencija "Nanomedicine - from theory to therapy", Aleksandrija, Egipat (2009): predavanja po pozivu "Nanoparticles for anticancer therapy" i "Biomedical potential of the reactive oxygen species generation and quenching by fullerenes".

3.4. Učestvovali su u rukovođenju međunarodnim projektima: Prof. dr Vladimir Trajković je nacionalni koordinator COST akcije CA15138 "European Network of Multidisciplinary Research and Translation of Autophagy knowledge" (TRANSAUTOPHAGY)

ZAKLJUČAK I MIŠLJENJE I PREDLOG KOMISIJE

Na raspisani konkurs za izbor jednog nastavnika u zvanju redovnog profesora za užu naučnu oblast Imunologija, koji je objavljen 05.07.2017. u publikaciji Nacionalne službe za zapošljavanje „Poslovi“, javio se jedan kandidat, dr Vladimir Trajković, dosadašnji vanredni profesor na Katedri za imunologiju.

Na osnovu izvršene analize dostavljene dokumentacije, kao i procene dosadašnje stručne, naučne i pedagoške i aktivnosti, stručna komisija smatra da je dr Vladimir Trajković ispunio sve uslove za izbor u zvanje redovnog profesora, pa predlaže Izbornom vešću fakulteta da utvrdi predlog za njegov izbor u zvanje redovnog profesora za užu naučnu oblast Imunologija na Medicinskom fakultetu Univerziteta u Beogradu.

U Beogradu, 08.09.2017.

POTPISILANOVA KOMISIJE

Prof. dr Dušan Popadi

Prof. dr Vera Pravica

Prof. emeritus dr Marija Mostarica Stojković